US equities |
GOOGL $283.82 ▼-12.64% GOOG $282.32 ▼-12.29% MU $934.27 ▼-4.98% MSFT $530.14 ▼-0.16% AMZN $243.79 ▼-4.25% META $624.52 ▲+1.96% NVDA $213.66 ▼-0.80% AAPL $348.91 ▲+1.48%
FinancialContent

Articles published by Scancell Holdings Plc

News headline image
Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study
From Scancell Holdings Plc
Via GlobeNewswire
Tickers LSE
News headline image
Interim Results for the six months ended 31 October 2025
From Scancell Holdings Plc
Via GlobeNewswire
Tickers LSE
News headline image
Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma
From Scancell Holdings Plc
Via GlobeNewswire
Tickers LSE
News headline image
Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ in patients with first line advanced melanoma
From Scancell Holdings Plc
Via GlobeNewswire
Tickers LSE
News headline image
Research Update
From Scancell Holdings Plc
Via GlobeNewswire
Tickers LSE
News headline image
Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025
From Scancell Holdings Plc
Via GlobeNewswire
Tickers LSE
News headline image
Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+
From Scancell Holdings Plc
Via GlobeNewswire
Tickers LSE